Abstract
AIMS
We aim to identify circulating prognostic biomarkers that accurately identify high risk meningioma whilst reducing the burden of invasive diagnostics. In our proteomic analysis, S100A4 and Fibulin-2 are significantly over expressed in grade 2 tumours compared to grade 1. They are both calcium-binding proteins with S100A4 involved in mesenchymal transition while Fibulin-2 helps scaffold the extracellular matrix. Elevated levels correlate with aggressive phenotypes in multiple cancers.
METHOD
Anonymised pre-operative meningioma blood samples were obtained from ‘The Plymouth Brain Tumour Biobank’ and ‘UK Brain Archive Information Network (BRAIN-UK)’. In total, 155 samples were analysed via Enzyme-Linked Immunosorbent Assay (ELISA) for serum S100A4 and plasma Fibulin-2. The Area Under the Receiver Operating Characteristic (ROC) curve (AUC) was used to examine the specificity and sensitivity of both markers.
RESULTS
Circulating levels of S100A4 were significantly (*p<0.05) higher in grade 2 meningiomas (mean 276.7 pg/mL (+/- 49.9 pg/mL) compared to grade 1 (mean 153.10 pg/mL +/- 20.68 pg/mL).
Serum S100A4 & plasma Fibulin-2 cut-off values of 344.8 pg/mL & 2500 pg/mL respectively have a 95% specificity for identifying patients with grade 2 tumours over grade 1.
To improve the diagnostic accuracy of grade 1 vs grade 2 samples, we combined S100A4 and Fibulin-2 concentrations to achieve an improved AUC of 0.682, *p<0.05.
CONCLUSIONS
Serum S100A4 is significantly higher in grade 2 compared to grade 1 meningiomas (95% sensitivity; cut off 344.8 pg/mL). Combining S100A4 and the previously published Fibulin-2 improves the accuracy of predicting grade 2 meningiomas.
We aim to identify circulating prognostic biomarkers that accurately identify high risk meningioma whilst reducing the burden of invasive diagnostics. In our proteomic analysis, S100A4 and Fibulin-2 are significantly over expressed in grade 2 tumours compared to grade 1. They are both calcium-binding proteins with S100A4 involved in mesenchymal transition while Fibulin-2 helps scaffold the extracellular matrix. Elevated levels correlate with aggressive phenotypes in multiple cancers.
METHOD
Anonymised pre-operative meningioma blood samples were obtained from ‘The Plymouth Brain Tumour Biobank’ and ‘UK Brain Archive Information Network (BRAIN-UK)’. In total, 155 samples were analysed via Enzyme-Linked Immunosorbent Assay (ELISA) for serum S100A4 and plasma Fibulin-2. The Area Under the Receiver Operating Characteristic (ROC) curve (AUC) was used to examine the specificity and sensitivity of both markers.
RESULTS
Circulating levels of S100A4 were significantly (*p<0.05) higher in grade 2 meningiomas (mean 276.7 pg/mL (+/- 49.9 pg/mL) compared to grade 1 (mean 153.10 pg/mL +/- 20.68 pg/mL).
Serum S100A4 & plasma Fibulin-2 cut-off values of 344.8 pg/mL & 2500 pg/mL respectively have a 95% specificity for identifying patients with grade 2 tumours over grade 1.
To improve the diagnostic accuracy of grade 1 vs grade 2 samples, we combined S100A4 and Fibulin-2 concentrations to achieve an improved AUC of 0.682, *p<0.05.
CONCLUSIONS
Serum S100A4 is significantly higher in grade 2 compared to grade 1 meningiomas (95% sensitivity; cut off 344.8 pg/mL). Combining S100A4 and the previously published Fibulin-2 improves the accuracy of predicting grade 2 meningiomas.
| Original language | English |
|---|---|
| Pages (from-to) | iii17-iii17 |
| Journal | June 2018Neuro-Oncology 20(suppl_2):i158-i158 DOI: 10.1093/neuonc/noy059.587 |
| Volume | 25 |
| Issue number | Supplement_3 |
| DOIs | |
| Publication status | Published - 16 Sept 2023 |